Skip to main content
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRS ISIN · US00461U1051 LEI · 5493000B2LQ9QTW1DF52 US Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2024-11-18 Director's Dealing
Country US United States of America
Listing US ACRS

About Aclaris Therapeutics, Inc.

https://www.aclaristx.com/

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel drug candidates for immuno-inflammatory diseases. The company leverages its core expertise in drug discovery, development, and kinase inhibition to create a pipeline of both small and large molecule drugs. Aclaris focuses on translating scientific discovery into innovative therapies to address the needs of patients with underserved conditions.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-11-18 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Aclaris Therapeutics, Inc. It includes multiple disclosures: entry into a material definitive agreement (license and collaboration agreements), a private placement financing, unregistered sales of equity securities, and appointment of a new President, COO, and director. The content covers material contracts and financing activities, as well as management changes. The primary focus is on the announcement of a material definitive agreement and a private placement financing, which are capital raising and financing activities. Additionally, it includes management appointment information. However, the dominant theme is the financing and capital raising update, including issuance of warrants and private placement shares. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document is detailed and substantive, not a brief announcement or a certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). The confidence in this classification is high given the clear focus on financing and capital structure changes.
2024-11-18 English
SC 13G/A
Major Shareholding Notification
2024-11-14 English
10-Q
Interim / Quarterly Report Q3 2024
2024-11-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Aclaris Therapeutics, Inc. It announces the issuance of a press release regarding financial results for the quarter and nine months ended September 30, 2024. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as an exhibit. The length is 3851 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the full earnings release or quarterly report itself. Therefore, the appropriate classification is Earnings Release (ER), as the document announces quarterly financial results via a press release.
2024-11-06 English
Director's Dealing 2024
Director's Dealing
2024-11-05 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.